Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction

New England Journal of Medicine

Volumn 368, Issue 15, 2013, Pages 1379-1387

  Armstrong, Paul W ^a   Gershlick, Anthony H ^b   Goldstein, Patrick ^d   Wilcox, Robert ^c   Danays, Thierry ^e   Lambert, Yves ^f   Sulimov, Vitaly ^g   Ortiz, Fernando Rosell ^h   Ostojic, Miodrag ⁱ   Welsh, Robert C ^a   Carvalho, Antonio C ^j   Nanas, John ^k   Hans Richard Arntz, Sigrun Halvorsen ^l,m   Huber, Kurt ⁿ   Grajek, Stefan ^o   Fresco, Claudio ^p   Bluhmki, Erich ^q   Regelin, Anne ^r   Vandenberghe, Katleen ^s   Bogaerts, Kris ^t,u   Van De Werf, Frans ^s   more..

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e BOEHRINGER INGELHEIM   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^h Empresa Pública de Emergencias Sanitarias de Andalucía   (Spain)

ⁱ UNIVERSITY OF BELGRADE   (Serbia)

^j FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^k UNIVERSITY OF ATHENS   (Greece)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁿ WILHELMINEN HOSPITAL   (Austria)

^o POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^p UNIVERSITY HOSPITAL OF UDINE   (Italy)

^q BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^r Boehringer Ingelheim   (Switzerland)

^s UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^t UNIVERSITY OF LEUVEN   (Belgium)

^u HASSELT UNIVERSITY   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; TENECTEPLASE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BOLUS INJECTION; BRAIN HEMORRHAGE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DRUG DOSE REDUCTION; EMERGENCY CARE; FEMALE; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHOCK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84875922206     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1301092     Document Type: Article

References (15)

1. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
2. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61(4):e78-e140.
3. Armstrong PW, Boden WE. Reperfusion paradox in ST-segment elevation myocardial infarction. Ann Intern Med 2011;155:389-91.
4. Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol 2010;56:254-63.
5. Terkelsen CJ, Sørensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 2010;304:763-71.
6. Pinto DS, Frederick PD, Chakrabarti AK, et al. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation 2011;124:2512-21.
7. Armstrong PW, Westerhout CM, Welsh RC. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Circulation 2009;119:1293-303.
8. Armstrong PW, Gershlick A, Goldstein P, et al. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J 2010;160(1):30.e1-35.e1.
9. Larson DM, Duval S, Sharkey SW, et al. Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural STelevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J 2012;33:1232-40.
10. Harrell FE Jr. Hmisc: Harrell Miscellaneous - R package, version 3.8-3. 2010 (http://cran.r-project.org/package=Hmisc).
11. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-42. (Pubitemid 37010777)
12. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367:569-78.
13. Brouwer MA, Martin JS, Maynard C, et al. Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] Randomized Trial). Am J Cardiol 1996;78:497-502. (Pubitemid 126658584)
14. Westerhout CM, Bonnefoy E, Welsh RC, Steg PG, Boutitie F, Armstrong PW. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am Heart J 2011;161:283-90.
15. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005;46:1986-95. (Pubitemid 41713579)